-
immune activation, cytotoxicity, and persistence. Additional methods may involve CRISPR-based perturbations, viral vector engineering, and immune cell manufacturing workflows relevant to CAR-based
-
activation, cytotoxicity, and persistence. Additional methods may involve CRISPR-based perturbations, viral vector engineering, and immune cell manufacturing workflows relevant to CAR-based therapies. In vivo
-
interest is to develop Adeno-associated virus (AAV) vectors to treat various diseases such as ocular blindness, and to study basic biology and virus host interaction. A major focus is vector engineering to
-
to evaluate immune activation, cytotoxicity, and persistence. Additional methods may involve CRISPR-based perturbations, viral vector engineering, and immune cell manufacturing workflows relevant to CAR-based